Wells Fargo & Company Forecasts Strong Price Appreciation for LeMaitre Vascular (NASDAQ:LMAT) Stock

Key Points

• Wells Fargo raised its price target on LeMaitre Vascular to $104 and kept an "equal weight" rating, while the analyst consensus averages a "Moderate Buy" with an average target of $107.80.
• Q1 results showed a slight EPS beat ($0.68 vs. $0.66) and 11.1% revenue growth, and management raised Q2 and FY2026 guidance (FY26 EPS 2.93–3.08) and declared a $0.25 quarterly dividend.
• Insider selling was significant—CEO George Lemaitre sold 150,000 shares and insiders sold ~215,438 shares (~$23M total)—and the stock traded down 5.6% to $105.74 on the report day.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) had its price objective increased by equities research analysts at Wells Fargo & Company from $94.00 to $104.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an "equal weight" rating on the medical instruments supplier's stock. Wells Fargo & Company's price target points to a potential downside of 1.65% from the stock's previous close.

Several other research analysts have also recently weighed in on the company. Wall Street Zen raised LeMaitre Vascular from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. Citizens Jmp upped their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 26th. Barrington Research upped their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Weiss Ratings raised LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, March 10th. Finally, Freedom Capital raised LeMaitre Vascular to a "hold" rating in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $107.80.

LeMaitre Vascular Stock Down 5.6%

Shares of LMAT stock traded down $6.26 on Wednesday, hitting $105.74. 46,841 shares of the stock were exchanged, compared to its average volume of 201,940. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $2.42 billion, a P/E ratio of 42.13, a price-to-earnings-growth ratio of 3.21 and a beta of 0.60. The business has a 50-day moving average of $109.28 and a 200 day moving average of $94.17. LeMaitre Vascular has a fifty-two week low of $78.35 and a fifty-two week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. The company had revenue of $66.55 million during the quarter, compared to analysts' expectations of $66.67 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.LeMaitre Vascular's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities analysts anticipate that LeMaitre Vascular will post 2.89 EPS for the current year.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 150,000 shares of the firm's stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total transaction of $16,014,000.00. Following the transaction, the chief executive officer owned 1,532,304 shares in the company, valued at $163,588,775.04. This trade represents a 8.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David B. Roberts sold 8,464 shares of the firm's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares in the company, valued at approximately $1,920,157.20. This represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 215,438 shares of company stock worth $23,062,911. Company insiders own 7.40% of the company's stock.

Institutional Investors Weigh In On LeMaitre Vascular

Large investors have recently modified their holdings of the business. Sound Income Strategies LLC boosted its holdings in shares of LeMaitre Vascular by 425.6% in the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 183 shares in the last quarter. Cornerstone Planning Group LLC boosted its holdings in shares of LeMaitre Vascular by 534.0% during the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 283 shares in the last quarter. MAI Capital Management acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at $38,000. First Horizon Corp acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter valued at $39,000. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock valued at $47,000 after acquiring an additional 398 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular News Summary

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q1 EPS topped expectations: $0.68 vs. consensus $0.66, up from $0.48 a year ago — supports earnings momentum. LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
• Positive Sentiment: Management raised guidance: Q2 EPS guided to $0.790–$0.840 (above consensus ~$0.760) and FY26 EPS to $2.930–$3.080 (vs. consensus ~2.90) — indicates confidence in continuing earnings growth. LeMaitre Q1 2026 Financial Results (press release / guidance)
• Positive Sentiment: Board declared a quarterly cash dividend of $0.25/share (ex-dividend May 21) — modest income support, though yield (~0.9%) is small. LeMaitre Q1 2026 Financial Results
• Neutral Sentiment: Revenue grew 11.1% year-over-year, showing solid top-line growth, but was essentially in line with expectations ($66.55M vs. $66.67M consensus). LeMaitre NASDAQ: LMAT Posts Q1 CY2026 Sales In Line With Estimates
• Neutral Sentiment: Full earnings release and conference call materials available for deeper review (transcript posted). Useful for investors wanting color on procedure volumes, margin drivers, and buyback/dividend plans. LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue slightly missed consensus by a small margin (about $0.12M), and the sales figure was effectively “in line” not a clear beat — reduces upside surprise potential. LeMaitre Q1 earnings report (MarketBeat)

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.